Navigation Links
Flurizan's Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimer's Disease is Superior to That of Aricept
Date:2/5/2008

Following its Launch in 2010, Myriad Genetics' Flurizan Will Earn a 23% Patient Share in the United States, According to a New Report from Decision

Resources

WALTHAM, Mass., Feb. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on delaying the progression from mild cognitive impairment to Alzheimer's disease is the attribute that most influences neurologists' prescribing decisions in the treatment of mild cognitive impairment. Clinical trial data and expert opinion shows that Myriad Genetics' Flurizan has advantages in this attribute over Eisai/Pfizer's Aricept/Bracco's Memac, the current sales leader and gold standard therapy for mild cognitive impairment.

The new report entitled Mild Cognitive Impairment: An Off-Label Market with Significant Unmet Need and High Prevalence Carries Substantial Opportunity finds that, following its launch in 2010, Flurizan will replace Aricept as the gold standard for mild cognitive impairment. Surveyed U.S. neurologists indicate that they would prescribe Flurizan to 20% of their patients with mild cognitive impairment and the report forecasts that Flurizan will earn a 23% patient share in the U.S. market in 2016.

"Clinical trial data suggests that Flurizan has disease-modifying properties, an asset that interviewed experts expect will make the drug more effective at delaying the onset of Alzheimer's disease than currently available drugs," said Bethany Kiernan, Ph.D., analyst at Decision Resources. "Flurizan's safety and tolerability profile is also better than other emerging competitors, and this, along with its efficacy, will make it the gold standard in the treatment of mild cognitive impairment in 2016."

About the Report

Mild Cognitive Impairment: An Off-Label Market with Significant Unmet Need and High Prevalence Carries Substantial Op
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
2. DNA sensors found to be an effective artificial nose
3. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
4. Job-related stress: NIST demonstrates fatigue effects in silicon
5. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
6. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
7. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
8. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
9. New nanoparticle vaccine is more effective but less expensive
10. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
11. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... HUYA Bioscience International (HUYA) today announced the sponsorship ... of HTLV-1, held this week at the University of ... Society is to promote research on HTLV-1 and HTLV-1-associated ... and research related to these fields to advance science, ... proud to support this prestigious conference," said Mireille ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... and expertly narrows down the product choices to a manageable shortlist of bench ... the list to models that fit best with the customer’s industry and application. ...
(Date:8/26/2015)... ... 2015 , ... MediVet Biologics, a leader in Veterinary Regenerative ... open in Manhattan, Kansas in early October, 2015. The location of the lab ... development through collaboration with researchers from Kansas State University’s College of Veterinary Medicine. ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, ... the development and manufacture of highly valued cardiac markers used in early detection ... expertise with protein chemistry has led to the development and commercialization of important ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... December - - PC-Insulin Preclinical Study Results ... Biotechnologies,Inc. (TSX:CJB) announced today that dosing is complete ... Phase II trial was a,randomized, double-blind, placebo-controlled, multiple ... three months of weekly injections of,PC-DAC(TM):Exendin-4 in patients ...
... NOVATO, Calif., Nov. 5 BioMarin,Pharmaceutical Inc. (Nasdaq: ... of BioMarin, will present a company,update at the Credit ... November 12, 2008 at 10:30 a.m. MST., Interested ... conference,call via the investor section of the BioMarin website, ...
... DIEGO, Nov. 5 Ambrx Inc. today announced ... clinical trial of ARX201,the company,s long-acting human growth ... at the International Congress of,Endocrinology meeting in Rio ... and Vice President of Academic Affairs at Stanford ...
Cached Biology Technology:ConjuChem Provides Development Update 2ConjuChem Provides Development Update 3BioMarin to Present at the Credit Suisse Healthcare Conference 2Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue 2
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Highlights from the Lymphoma Research Foundation (LRF) 2009 Mantle Cell ... the March 2010 issue of Leukemia & Lymphoma. Traditionally ... Lymphoma has agreed to make this report available to the ... of the 2009 MCL Consortium Workshop. "It is gratifying ...
... Resistant wheat plants stave off attacks by Hessian fly larvae ... absorb nutrients, according to a study by Purdue University and ... - similar to human intestines - were observed in three ... function. Those that were given nothing to eat showed no ...
... Allergies and Infectious Diseases (NIAID), part of the National ... totaling $15,254,919 to Tulane University for its ongoing efforts ... viral disease that threatens hundreds of thousands of people ... potential bioterrorism threat. The contract will include collaboration ...
Cached Biology News:Resistant wheat goes for the gut to protect against Hessian flies 2Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
ANTI S. ENTERID LPS...
... ELISA Development kit contains the basic components ... to measure natural and recombinant Feline IL-10 ... kit contains sufficient materials to run ELISAs ... the following conditions are met: The ...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant rat ... Each kit contains sufficient materials to ... provided that the following conditions are met: ...
Biology Products: